Ident. | Authors (with country if any) | Title |
---|
000003 |
Stéphanie Bissonnette [Canada] ; Sophie Muratot [Canada] ; Nathalie Vernoux [Canada] ; François Bezeau [Canada] ; Frédéric Calon [Canada] ; Sébastien S. Hebert [Canada] ; Pershia Samadi [Canada] | The effect of striatal pre-enkephalin overexpression in the basal ganglia of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease |
000014 |
Nicolas Morin [Canada] ; Vincent A. Jourdain ; Thérèse Di Paolo | Modeling dyskinesia in animal models of Parkinson disease : ANIMAL MODELS OF PARKINSON'S DISEASE |
000083 |
Alexander C. Sutton [États-Unis] ; Wilson Yu [États-Unis] ; Megan E. Calos [États-Unis] ; Lauren E. Mueller [États-Unis] ; Matthew Berk [États-Unis] ; Jenny Shim [États-Unis] ; Eric S. Molho [États-Unis] ; Jonathan M. Brotchie [Canada] ; Peter L. Carlen [Canada] ; Damian S. Shin [États-Unis] | Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat |
000095 |
Christopher Kobylecki [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada] | Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia |
000115 |
D. Domenger [Canada] ; D. Dea [Canada] ; L. Theroux [Canada] ; L. Moquin [Canada] ; A. Gratton [Canada] ; J. Poirier [Canada] | The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain |
000164 |
D. W. Luchtman [Canada] ; Q. Meng [Canada] ; C. Song [Canada, République populaire de Chine] | Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease |
000197 |
YILONG MA [États-Unis] ; SHUCHUN PENG [États-Unis] ; Phoebe G. Spetsieris [États-Unis] ; Vesna Sossi [Canada] ; David Eidelberg [États-Unis] ; Doris J. Doudet [Canada] | Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism |
000226 |
Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill [Canada] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada] | Synergistic Antidyskinetic Effects of Topiramate and Amantadine in Animal Models of Parkinson's Disease |
000249 |
RUITAO WANG [Canada, République populaire de Chine] ; MINGMING ZHANG [Canada] ; WEIHUI ZHOU [Canada] ; Philip T. T. Ly [Canada] ; FANG CAI [Canada] ; WEIHONG SONG [Canada] | NF-κB signaling inhibits ubiquitin carboxyl-terminal hydrolase L1 gene expression |
000361 |
Bazoumana Ouattara [Canada] ; Fabrizio Gasparini [Suisse] ; Marc Morissette [Canada] ; Laurent Gregoire [Canada] ; Pershia Samadi [Canada] ; Baltazar Gomez-Mancilla [Suisse] ; Thérèse Di Paolo [Canada] | Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys |
000409 |
Grace Lee [Canada] ; Tony Chu [Canada] ; Christopher A. Shaw [Canada] | The primary locus of motor neuron death in an ALS-PDC mouse model |
000433 |
M. Bousquet [Canada] ; C. Gibrat [Canada] ; M. Saint-Pierre [Canada] ; C. Julien [Canada] ; F. Calon [Canada] ; F. Cicchetti [Canada] | Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model |
000478 |
Vesna Sossi [Canada] ; Katherine Dinelle [Canada] ; Geoffrey J. Topping [Canada] ; James E. Holden [États-Unis] ; Doris Doudet [Canada] ; Michael Schulzer [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] ; Raul De La Fuente-Femandez [Canada] | Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's : an in vivo imaging study |
000481 |
Claire Gibrat [Canada] ; Martine Saint-Pierre [Canada] ; Mélanie Bousquet [Canada] ; Daniel Levesque [Canada] ; Claude Rouillard [Canada] ; Francesca Cicchetti [Canada] | Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α-synuclein inclusions |
000491 |
Dirk W. Luchtman [Canada] ; DI SHAO [Canada] ; CAI SONG [Canada] | Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease |
000492 |
N. M. Jadavji [Canada] ; G. A. Metz [Canada] | BOTH PRE-AND POST-LESION EXPERIENTIAL THERAPY IS BENEFICIAL IN 6-HYDROXYDOPAMINE DOPAMINE-DEPLETED FEMALE RATS |
000514 |
Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis] | Striatal histone modifications in models of levodopa-induced dyskinesia |
000530 |
Y.-Y. Lai [États-Unis] ; K.-C. Hsieh [États-Unis] ; D. Nguyen [États-Unis] ; J. Peever [Canada] ; J. M. Siegel [États-Unis] | NEUROTOXIC LESIONS AT THE VENTRAL MESOPONTINE JUNCTION CHANGE SLEEP TIME AND MUSCLE ACTIVITY DURING SLEEP : AN ANIMAL MODEL OF MOTOR DISORDERS IN SLEEP |
000614 |
Anne M. Landau [Canada] ; Edouard Kouassi [Canada] ; Rosmarie Siegrist-Johnstone [Canada] ; Julie Desbarats [Canada] | Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle |
000647 |
Ivan L. Cepeda [Canada] ; Joseph Flores [Canada] ; Michael L. Cornfeldt [États-Unis] ; John R. O'Kusky [Canada] ; Doris J. Doudet [Canada] | Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of parkinson disease |
000654 |
Philippe Huot [Canada] ; André Parent [Canada] | Dopaminergic neurons intrinsic to the striatum |
000683 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies : Keys to success and roads to failure |
000690 |
Martine Saint-Pierre [Canada] ; Marie-Eve Tremblay [Canada] ; Attila Sik [Canada] ; Robert E. Gross [États-Unis] ; Francesca Cicchetti [Canada] | Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats |
000695 |
Evelyn F. Field [Canada] ; Gerlinde A. Metz [Canada] ; Sergio M. Pellis [Canada] ; Ian Q. Whishaw [Canada] | Sexually dimorphic postural adjustments during vertical behaviour are altered in a unilateral 6-OHDA rat model of Parkinson's disease |
000710 |
Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
000731 |
N. M. Jadavji [Canada] ; B. Kolb [Canada] ; G. A. Metz [Canada] | Enriched environment improves motor function in intact and unilateral dopamine-depleted rats |
000798 |
J. M. B. Wilson [Canada] ; M. S. Petrik [Canada] ; M. H. Moghadasian [Canada] ; C. A. Shaw [Canada] | Examining the interaction of apo E and neurotoxicity on a murine model of ALS-PDC |
000826 |
Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease |
000838 |
J. E. Nash [Canada] ; P. Ravenscroft [Royaume-Uni] ; S. Mcguire [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; F. S. Menniti [États-Unis] ; J. M. Brotchie [Canada] | The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease |
000853 |
Gerlinde A. Metz [Canada] ; Dionne M. Piecharka [Canada] ; Jeffrey A. Kleim [Canada] ; Ian Q. Whishaw [Canada] | Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease |
000934 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
000A16 |
Ian Q. Whishaw [Canada] ; Oksana Suchowersky [Canada] ; Leigh Davis [Canada] ; Justyna Sarna [Canada] ; Gerlinde A. Metz [Canada] ; Sergio M. Pellis [Canada] | Impairment of pronation, supination, and body co-ordination in reach-to-grasp tasks in human Parkinson's disease (PD) reveals homology to deficits in animal models |
000A22 |
Michel Cyr [Canada] ; Frederic Calon [Canada] ; Marc Morissette [Canada] ; Thérèse Di Paolo [Canada] | Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease |
000A27 |
G. A. Metz [Canada] ; I. Q. Whishaw [Canada] | Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance |
000A43 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Othman Ghribi [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Pierre J. Blanchet [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Alteration of glutamate receptors in the striatum of dyskinetic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment |
000A65 |
Pierre J. Blanchet [Canada] ; Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Daniel Levesque [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model |
000A86 |
K. Tieu [Canada] ; P. C. Ashe [Canada] ; D. M. Zuo [Canada] ; P. H. Yu [Canada] | Inhibition of 6-hydroxydopamine-induced p53 expression and survival of neuroblastoma cells following interaction with astrocytes |
000B20 |
Eric R. Marcotte [Canada] ; Anita Chugh [Canada] ; Cia Barlas [Canada] ; Ram K. Mishra [Canada] | Differential regulation of striatal G protein levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration in C57 BL/6 mice |
000B56 |
I. Mendez [Canada] ; K. A. Baker [Canada] ; M. Hong [Canada] | Simultaneous intrastriatal and intranigral grafting (double grafts) in the rat model of Parkinson's disease |
000B57 |
E. F. Field [Canada] ; I. Q. Whishaw [Canada] ; S. M. Pellis [Canada] | Sex differences in catalepsy : evidence for hormone-dependent postural mechanisms in haloperidol-treated rats |
000B68 |
M. Grandbois [Canada] ; M. Morissette [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice |
000B78 |
I. Mendez [Canada] ; M. Hong ; S. Smith ; A. Dagher ; J. Desrosiers | Neural transplantation cannula and microinjector system : experimental and clinical experience : Technical note |
000B81 |
F. Calon [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; P. J. Blanchet [Canada] ; T. T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Molecular basis of levodopa-induced dyskinesias |
000B95 |
J. M. Van Kampen [Canada] ; A. J. Stoessl [Canada] | Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia |
000C52 |
A. Richter [Allemagne] ; U. Ebert [Allemagne] ; J. N. Nobrega [Canada] ; J. J. Vallbacka [Canada] ; M. Fedrowitz [Allemagne] ; W. Löscher [Allemagne] | Immunohistochemical and neurochemical studies on nigral and striatal functions in the circling (ci) rat, a genetic animal model with spontaneous rotational behavior |
000C59 |
T. A. Reader [Canada] ; K. M. Dewar [Canada] | Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum : implications for human Parkinson's disease |
000C73 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; A. Hadj Tahar [Canada] ; L. Gregoire [Canada] ; A. Mori [Japon] ; H. Kase [Japon] | Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys |
000D18 |
V. Mehta [Canada] ; M. Hong [Canada] ; J. Spears [Canada] ; I. Mendez [Canada] | Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor |
000D22 |
S. J. Crocker [Canada] ; M. Morelli [Italie] ; N. Wigle [Canada] ; Y. Nakabeppu [Japon] ; G. S. Robertson [Canada] | D1-receptor-related priming is attenuated by antisense-meditated 'knockdown' of fosB expression |
000D94 |
M. Goulet [Canada] ; M. Morissette [Canada] ; F. Calon [Canada] ; P. J. Blanchet [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression : In situ hybridization histochemical analysis |
000E10 |
D. J. Martens [Canada] ; I. Q. Whishaw [Canada] ; E. I. Miklyaeva [Canada] ; S. M. Pellis [Canada] | Spatio-temporal impairments in limb and body movements during righting in an hemiparkinsonian rat analogue : relevance to axial apraxia in humans |
000E29 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
000E34 |
C. V. Borlongan [États-Unis] ; T. B. Freeman ; R. A. Hauser ; D. W. Cahill ; P. R. Sanberg ; R. R. Tasker | Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism : Relevance to neural transplantation. Commentary |
000E61 |
E. I. Miklyaeva [Canada] ; D. J. Martens ; I. Q. Whishaw | Impairments and compensatory adjustment in spontaneous movement after unilateral dopamine depletion in rats |
000E83 |
M. Filion [Canada] ; L. Tremblay ; M. Matsumura ; H. Richard | Focalisation dynamique de la convergence informationnelle dans les noyaux gris centraux |
000F59 |
L. Rioux [Canada] ; C. Gagnon ; D. P. Gaudin [Canada] ; T. Di Paolo ; P. J. Bedard [Canada] | A fetal nigral graft prevents behavioral supersensitivity associated with repeated injections of L-dopa in 6-OHDA rats. Correlation with D1 and D2 receptors |
000F70 |
H. A. Robertson [Canada] ; M. R. Peterson ; G. G. Worth | Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243 |
000F78 |
L. C. Doering [Canada] | Peripheral nerve segments promote consistent long-term survival of adrenal medulla transplants in the brain |
001024 |
J. C. S. Furtado [Canada] ; M. F. Mazurek | MPTP-induced neurotoxicity and the quest for a preventative therapy for Parkinson's disease |
001058 |
M. Guttman ; H. C. Fibiger ; A. Jakubovic ; D. B. Calne | Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism |
001131 |
T. L. Perry ; K. Jones ; S. Hansen ; R. A. Wall | 2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease |
001149 |
T. L. Perry ; S. Hansen ; K. Jones | Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice |
001153 |
J. M. Radke ; P. Cumming ; S. R. Vincent | Effects of MPTP poisoning on central somatostatin and substance P levels in the mouse |